InsiderPulse
← 10-K / 10-Q
10-QTDAC

Translational Development Acquisition Corp.

Filed 2026-05-15Period ending 2026-03-31
EDGAR ↗All periods →

Income Statement

Line Item2026-03-31Q/QY/Y
SG&A Expense$281K-19.1%
Operating Income-$281K+19.1%
Income Tax$0
Net Income$1.3M-10.1%

Balance Sheet

Line Item2026-03-31Q/QY/Y
Cash & Equivalents$25K-17.3%-88.1%
Current Assets$75K+90.8%-81.9%
Total Assets$183.3M+0.9%+3.8%
Current Liabilities$861K+58.3%+166.7%
Total Liabilities$6.9M+4.8%+8.5%
Stockholders' Equity-$6.8M-4.3%-14.8%

Cash Flow

Line Item2026-03-31Q/QY/Y
Operating Cash Flow-$305K-31.8%
Financing Cash Flow$300K